Replimune's Approval Saga Offers a Case Study in Post-Makary FDA Engagement

Introduction

Replimune's journey to FDA approval for Tudriqev (vusolimogene oderparepvec-wtpg) has become an important case study in how biotechnology companies can navigate regulatory uncertainty, particularly after a period of contentious interactions with the agency.

The therapy was rejected twice before receiving accelerated approval on August 6, 2026, on its third submission. The turnaround followed a change in FDA leadership, renewed engagement between Replimune and the agency, and a July advisory committee vote that found the drug's efficacy results evaluable and clinically meaningful. (Reuters)

The episode offers broader lessons about regulatory communication, trial design, agency engagement, and the role of advisory committees in resolving difficult questions around innovative therapies.

A Regulatory Journey Marked by Two Rejections

Replimune first submitted its application for RP1, later branded Tudriqev, in November 2024.

The FDA rejected the application in July 2025, followed by a second rejection in April 2026. The agency's concerns centered in part on the evidence generated by the IGNYTE study, which was a single-arm trial without a randomized control group. Regulators also had questions about how much of the observed benefit could be attributed specifically to RP1 because it was administered in combination with nivolumab. (Reuters)

For Replimune, the repeated setbacks created an increasingly difficult regulatory environment and raised broader questions about how the FDA was evaluating the company's clinical evidence.

The Makary-Era Dispute

The controversy became particularly visible during the tenure of former FDA Commissioner Marty Makary.

Replimune and other industry observers questioned aspects of the agency's review process, while Makary defended the FDA's position and emphasized the importance of rigorous evidence for approval.

The disagreement was not simply about whether RP1 worked. It reflected a larger regulatory question: how much evidence should be required for an innovative therapy targeting patients with advanced disease and limited treatment options?

A single-arm study can demonstrate a treatment signal, but it does not provide the same comparative certainty as a randomized controlled trial. That distinction became central to the FDA's review.

Post-Makary Engagement Changed the Regulatory Trajectory

Following Makary's departure and changes in FDA leadership, Replimune pursued another regulatory path.

The company and agency established a route for a third submission, with the FDA accepting the resubmitted biologics license application in June 2026 and assigning an August 2 action date. The agency also indicated that an advisory committee meeting would be held in late July. (Replimune Group Inc.)

This represented an important shift from the previous regulatory encounters.

Rather than simply resubmitting the same application, the third review involved renewed engagement around the outstanding clinical and regulatory questions. The process demonstrates how continued dialogue between a sponsor and regulators can become critical when disagreements arise over evidence interpretation.

The Advisory Committee Became the Turning Point

The decisive moment came on July 30, 2026, when an FDA advisory committee reviewed Replimune's application.

Committee members were asked to assess whether the efficacy results from the IGNYTE study were evaluable and clinically meaningful. They voted 10–3 in favor, providing a strong positive signal ahead of the FDA's final decision. (U.S. Food and Drug Administration)

Although advisory committee votes are not binding on the FDA, the outcome helped change the regulatory narrative surrounding Tudriqev.

The committee effectively concluded that, despite the limitations of the trial design, the available clinical evidence provided a meaningful enough signal to support regulatory consideration.

Clinical Evidence Behind the Turnaround

The IGNYTE study enrolled 140 patients with advanced melanoma whose disease had progressed following anti-PD-1-based therapy.

Among the 91 patients in the efficacy-evaluable population with at least one non-injected lesion, Tudriqev plus nivolumab produced an objective response rate of 24.2%, while the median duration of response was 14.1 months. (Reuters)

These results were particularly important because the treatment was being evaluated in a difficult-to-treat population with limited therapeutic alternatives.

The FDA ultimately granted accelerated approval based on these efficacy measures, while requiring additional evidence to verify clinical benefit. (U.S. Food and Drug Administration)

What Changed in the Third Review?

The Replimune case illustrates an important distinction between regulatory disagreement and regulatory dead ends.

The earlier rejections did not necessarily mean that the underlying therapy had no clinical activity. Instead, they reflected uncertainty over whether the existing evidence was sufficiently persuasive for approval.

The third review created an opportunity for the agency to reconsider the evidence in the context of the company's updated submission, additional analyses, advisory committee input, and the unmet medical need in the target population.

This suggests that sustained, evidence-based engagement with regulators can be particularly important when a company's interpretation of its clinical data differs from the agency's.

Approval Finally Ends the Immediate Regulatory Battle

On August 6, 2026, the FDA granted accelerated approval to Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed following an anti-PD-1-based regimen. (U.S. Food and Drug Administration)

The decision made Tudriqev Replimune's first approved product and transformed the company from a primarily clinical-stage biotechnology company into a commercial oncology business. (Reuters)

However, the approval does not eliminate the questions that surrounded the earlier submissions.

The Regulatory Relationship Is Still Important

Replimune's work with the FDA does not end with approval.

Because Tudriqev received accelerated approval, the company must continue conducting confirmatory research to verify clinical benefit. A Phase 3 trial is underway, with results expected around 2030. (Reuters)

This creates a new phase of regulatory engagement.

The company must now maintain communication with the agency while generating the evidence needed to establish Tudriqev's long-term clinical value. The success of this relationship could be just as important as the third submission itself.

Lessons for Other Biotechnology Companies

The Replimune saga offers several lessons for drug developers.

1. Trial Design Can Determine Regulatory Flexibility

Promising response rates may not be sufficient if regulators believe the study design limits the ability to establish causality.

Companies developing therapies for difficult-to-treat diseases therefore need to anticipate questions about control groups, attribution of benefit, endpoint selection, and durability well before submitting an application.

2. Regulatory Communication Matters

The case demonstrates how disagreements over scientific interpretation can escalate when companies and regulators have different expectations.

Maintaining clear communication about evidence requirements and addressing concerns early can potentially reduce the risk of repeated regulatory setbacks.

3. Advisory Committees Can Help Resolve Complex Questions

The 10–3 advisory committee vote provided an independent assessment of the clinical evidence at a critical point in the review.

For controversial applications, advisory committees can give regulators additional expert perspectives on whether clinical findings are meaningful in the context of the disease and available treatment options.

4. Accelerated Approval Is a Beginning, Not an Endpoint

Tudriqev's approval provides Replimune with commercial access to the market, but the company must still demonstrate confirmed clinical benefit.

The ongoing Phase 3 program will therefore remain central to the drug's long-term regulatory position.

A Broader Case Study in FDA Engagement

The most significant lesson from Replimune's experience may be that FDA engagement is not a single event tied to one application.

Drug development involves years of interaction between companies and regulators, and scientific disagreements can evolve as new evidence becomes available.

Tudriqev's progression from two rejections to accelerated approval illustrates how regulatory outcomes can change when sponsors continue to address concerns, provide additional analyses, engage with agency officials, and obtain independent expert review.

For smaller biotechnology companies, this can be especially important because regulatory setbacks can consume significant financial resources and potentially threaten a program's viability.

Conclusion

Replimune's approval saga provides a striking example of the complexities involved in bringing an innovative oncology therapy through the FDA.

After two rejections during the earlier regulatory process, the company successfully secured a third review, received a favorable 10–3 advisory committee vote, and ultimately obtained accelerated approval for Tudriqev. (Reuters)

The case demonstrates that regulatory engagement does not necessarily end when an application is rejected. For biotechnology companies, persistent scientific dialogue, careful analysis of regulatory concerns, and willingness to generate additional evidence can reshape the trajectory of a development program.

For Replimune, however, the next test has already begun. Tudriqev's commercial launch and confirmatory Phase 3 evidence will determine whether its post-Makary regulatory turnaround becomes a lasting success or simply the next chapter in a complicated approval story.